PET/Computed Tomography in Breast Cancer: Can It Aid in Developing a Personalized Treatment Design?

Sumeet Suresh Malapure; Kalpa Jyoti Das; Rakesh Kumar

doi:10.1016/j.cpet.2016.02.006

PET/Computed Tomography in Breast Cancer: Can It Aid in Developing a Personalized Treatment Design?

Sumeet Suresh Malapure
, Kalpa Jyoti Das
, Rakesh Kumar^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

3 Citations (Scopus)

Abstract

PET with fluorodeoxyglucose (FDG-PET)/computed tomography (CT) imaging has significantly improved the management of breast cancer. FDG, however, is not tumor-specific and various image interpretation pitfalls may occur due to false-positive and false-negative causes of FDG uptake. PET/CT imaging with more specific radiopharmaceuticals may provide useful information about the pathophysiology in such cases. In the present article, we reviewed the use of whole-body FDG-PET/CT and ¹⁸F-16α-17β-Fluoroestradiol PET/CT imaging to determine if these can be used to develop personalized treatment design for the better management of breast cancer.

Original language	English
Pages (from-to)	297-303
Number of pages	7
Journal	PET Clinics
Volume	11
Issue number	3
DOIs	https://doi.org/10.1016/j.cpet.2016.02.006
Publication status	Published - 01-07-2016
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Radiation
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.cpet.2016.02.006

Cite this

@article{d91346c3bc884a1da30dd7186b3e1f60,

title = "PET/Computed Tomography in Breast Cancer: Can It Aid in Developing a Personalized Treatment Design?",

abstract = "PET with fluorodeoxyglucose (FDG-PET)/computed tomography (CT) imaging has significantly improved the management of breast cancer. FDG, however, is not tumor-specific and various image interpretation pitfalls may occur due to false-positive and false-negative causes of FDG uptake. PET/CT imaging with more specific radiopharmaceuticals may provide useful information about the pathophysiology in such cases. In the present article, we reviewed the use of whole-body FDG-PET/CT and 18F-16α-17β-Fluoroestradiol PET/CT imaging to determine if these can be used to develop personalized treatment design for the better management of breast cancer.",

author = "\{Suresh Malapure\}, Sumeet and Das, \{Kalpa Jyoti\} and Rakesh Kumar",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Inc.",

year = "2016",

month = jul,

day = "1",

doi = "10.1016/j.cpet.2016.02.006",

language = "English",

volume = "11",

pages = "297--303",

journal = "PET Clinics",

issn = "1556-8598",

publisher = "W.B. Saunders",

number = "3",

}

TY - JOUR

T1 - PET/Computed Tomography in Breast Cancer

T2 - Can It Aid in Developing a Personalized Treatment Design?

AU - Suresh Malapure, Sumeet

AU - Das, Kalpa Jyoti

AU - Kumar, Rakesh

PY - 2016/7/1

Y1 - 2016/7/1

N2 - PET with fluorodeoxyglucose (FDG-PET)/computed tomography (CT) imaging has significantly improved the management of breast cancer. FDG, however, is not tumor-specific and various image interpretation pitfalls may occur due to false-positive and false-negative causes of FDG uptake. PET/CT imaging with more specific radiopharmaceuticals may provide useful information about the pathophysiology in such cases. In the present article, we reviewed the use of whole-body FDG-PET/CT and 18F-16α-17β-Fluoroestradiol PET/CT imaging to determine if these can be used to develop personalized treatment design for the better management of breast cancer.

AB - PET with fluorodeoxyglucose (FDG-PET)/computed tomography (CT) imaging has significantly improved the management of breast cancer. FDG, however, is not tumor-specific and various image interpretation pitfalls may occur due to false-positive and false-negative causes of FDG uptake. PET/CT imaging with more specific radiopharmaceuticals may provide useful information about the pathophysiology in such cases. In the present article, we reviewed the use of whole-body FDG-PET/CT and 18F-16α-17β-Fluoroestradiol PET/CT imaging to determine if these can be used to develop personalized treatment design for the better management of breast cancer.

UR - https://www.scopus.com/pages/publications/84963954460

UR - https://www.scopus.com/pages/publications/84963954460#tab=citedBy

U2 - 10.1016/j.cpet.2016.02.006

DO - 10.1016/j.cpet.2016.02.006

M3 - Review article

C2 - 27321033

AN - SCOPUS:84963954460

SN - 1556-8598

VL - 11

SP - 297

EP - 303

JO - PET Clinics

JF - PET Clinics

IS - 3

ER -

PET/Computed Tomography in Breast Cancer: Can It Aid in Developing a Personalized Treatment Design?

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this